EI
AMLX icon

EAM Investors’s Amylyx Pharmaceuticals AMLX Stock Holding History

EAM Investors’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$740K Hold
53,256
– – 0.09% 236
2025
Q4 		$643K Sell
53,256
-21,855
-29% -$297K 0.07% 246
2025
Q3 		$1.02M Sell
75,111
-24,849
-25% -$234K 0.12% 191
2025
Q2 		$641K Buy
+99,960
New +$486K 0.1% 197
2023
Q1 		– Sell
-65,272
Closed -$2.41M – 252
2022
Q4 		$2.41M Buy
+65,272
New +$2.32M 0.5% 64

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

EAM Investors's AMLX Position: Q1 2026 in Review

EAM Investors held its Amylyx Pharmaceuticals (AMLX) position steady in Q1 2026 at 53,256 shares worth $740K. The position accounts for 0.09% of the portfolio, ranked #236.

EAM Investors first reported a position in AMLX in Q4 2022 and has held it in 5 quarters since. The position peaked at $2.41M in Q4 2022. 171 funds tracked by Wall St. Rank hold AMLX as of Q1 2026.

  • EAM Investors held 53,256 shares of Amylyx Pharmaceuticals worth $740K as of Q1 2026.
  • EAM Investors left its Amylyx Pharmaceuticals share count unchanged in Q1 2026.
  • Amylyx Pharmaceuticals made up 0.09% of EAM Investors's portfolio in Q1 2026, its #236 holding.
  • EAM Investors first reported a position in Amylyx Pharmaceuticals in Q4 2022 and has held it in 5 quarters since.
  • EAM Investors's Amylyx Pharmaceuticals position peaked at $2.41M in Q4 2022.
  • 171 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q1 2026.

Based on EAM Investors's 13F filing for Q1 2026, filed 13 May 2026.